Own research center
performs a full development cycle: from the molecule
before registration of the drug. Biotech development
drugs - the priority of the company.
Production of active pharmaceutical substances. After reaching the design capacity the company will be able to cover Russian needs in insulin for 100 % and to expand export opportunities
A leading full-cycle producer of gene-engineering human insulin – from synthesis of a substance to finished dosage form. The plant can cover 30 % of Russian needs in insulin